teamlab Biovortex Kyoto Set To Open This Fall
Summary
Opening this fall, teamLab Biovortex Kyoto will be the latest permanent immersive art museum by the acclaimed collectiveteamLab. Located nearKyotoStation, the museum is part of the city's broader urban revitalization initiative. This project aims to establish a dynamic cultural and creative hub, fostering a new synergy around art, youth, and innovation.
The concept behind 'Biovortex' suggests a swirling center of life and interconnectedness, themes deeply resonant with teamLab's artistic philosophy. Among the highlighted installations, 'Massless Amorphous Sculpture' stands out as a floating, shape-shifting entity, composed of foam-like material that maintains its form even when people enter it. This piece embodies teamLab's exploration of masslessness, creating a seamless blend of digital and tangible elements.
The immersive journey continues with other key works designed to challenge perception. 'Massless Suns and Dark Suns' presents a constellation of glowing orbs that shift based on human presence. As visitors widen their perception, dark spheres emerge, existing solely within the viewer's cognitive reality, making each experience uniquely personal. Another installation, 'Morphing Continuum,' is designed to stretch across both space and time, continuously regenerating as visitors immerse themselves within it. Additionally, 'Traces of Life' offers an interactive experience where visitors' movements create ephemeral trails, symbolizing the interconnectedness of individuals within the art space.
Unlike teamLab Planets Tokyo or teamLab Borderless, which feature seasonal themes, teamLab Biovortex Kyoto will showcase a rotating selection of immersive works, ensuring a constantly evolving experience for returning visitors. For more information, visit teamlab's officialwebsite.
teamLab Biovortex Kyoto20-1 Higashikujo Higashiiwamotocho,Minami Ward, Kyoto, 601-8006, Japan
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
an hour ago
- Chicago Tribune
Review: Giancarlo Guerrero steps into new Grant Park Music Fest role with a pair of genial and dynamic programs
Talk about a perfect storm. On Wednesday, Giancarlo Guerrero's much-fêted debut as principal conductor and artistic director of the Grant Park Music Festival was dampened by relentless rain. Audiences scrunched under the Jay Pritzker Pavilion fringe, only to play musical chairs dodging the structure's many (and ever-changing) leaky spots. When they weren't doing that, seat shuffles and squabbles competed with the evening's violin concerto. But if Guerrero appeared unflappable onstage, it's because he's been there before. He made his sophomore appearance with the orchestra in 2014 under nearly identical circumstances, down to the solo string showcase and contemporary American opener. Despite the lousy weather, that appearance impressed festival musicians enough to fast-track Guerrero to the top of their director wishlist a decade later. While last week's storm never erupted into thunder, musical lightning struck twice here with yet another exuberant, water-resistant stand by Guerrero on Wednesday, followed by a masterful account of Mahler's Symphony No. 1 on Friday. Wednesday's concert included two harbor works: 'An American Port of Call,' by Virginia-based composer Adolphus Hailstork, and Leonard Bernstein's 'On the Waterfront' suite. Conducting with his pointer fingers rather than a baton, and sporting a new goatee, Guerrero led a sparky, whistle-clean run of Hailstork's eight-minute curtain raiser. But when the music dissipated into quietude — recalling a boat drifting far off from shore, surrounded only by blue horizon — Guerrero guided the music with expansive ease. Bernstein's 'Waterfront' benefited from the same balance of gusto and intuitive pacing. Patrick Walle's horn solo up top sounded suspended in time, before an increasingly feral orchestra jerked us back to street level. Amid the ferocity, the Grant Parkers always sounded whetted and clean, moving through the works' shifting meters with fearsome precision. In the final windup to the end, electric energy gave way to ringing, Mussorgskyan grandeur. Between the Hailstork and Bernstein, Jeremy Black returned to the festival as both concertmaster and featured soloist, offering up the Mendelssohn Violin Concerto. Even the brunt of the evening's downpour couldn't wash away the strong impression left by this filigree, soulful performance. Black's sound in the opening theme and balladic second movement was sugared but never treacly. Meanwhile, the Allegro molto vivace coasted along serenely, Black's bel canto phrasing and pristine intonation never betraying its finger-flying briskness. Promisingly, Guerrero's orchestral accompaniment was every bit as tasteful. Negotiating solo string balance in the park is always just that — a negotiation — but Guerrero hit the sweet spot of clarity and restraint. The orchestra was able to be a bit more gutsy under Friday's soloist, Pacho Flores. The Venezuelan trumpeter has a sparkling sound, which he dispatched with doting attention to phrase and line in Arturo Márquez's lively, if unseasonal, 'Concierto de Otoño' ('Autumn Concerto'). The work was specifically composed for Flores in 2018, taking unabashed advantage of not just the trumpeter's lyricism but his gatling-gun articulation, unflappable stamina and chameleon flexibility. (He traded four different horns across the 20-minute piece: C and D trumpets in the outer movements, then a flugelhorn and soprano cornet in the middle.) Flores also knows how to work a crowd. Rather than shooting to the stratosphere in his third-movement cadenza, he crawled to the bottom of his range — an amusing subversion of trumpet tropes. He then turned his bell directly at Guerrero and playfully pppththhed at him through his horn, prompting a teasing 'what gives?' shrug from the conductor. That said, it's hard to endorse Márquez's concerto beyond a mere virtuoso vehicle. The orchestral backing is often trite, cycling through the same progressions for what feels like minutes at a time. If the concerto's many flavors of theme-and-variation were engrossing at all, it was entirely thanks to Friday's soloist and orchestra, both playing with tempera-rich color and joie d'vivre. For pops-adjacent music under a more skillful hand, look to Flores himself. He opened and closed his appearance with two self-penned numbers: 'Morocota' (named for a $20 Venezuelan coin) and 'Lábios Vermelhos' ('Red Lips'). Originally recording both with guitar accompaniment for a 2017 Deutsche Grammophon release, Flores sang through his horn with a suave melodiousness that would have done the Rat Pack proud, with just a shimmer of vibrato where it counted. His lush orchestral arrangements would have been right at home in that milieu, too. At one point in 'Lábios Vermelhos,' section trumpets got in on the fun, with a sneering little interjection. Yet another short, Latin-inspired curtain raiser opened the concert: 'Baião n' Blues,' by Chicago composer Clarice Assad. A staple of the Carlos Kalmar years, Assad's inclusion in Guerrero's opening week bodes well for the new festival chief's attention to local composers. Ultimately, though, this performance had some of the same early-season jitters as last week's opener, with a scraggly opening and subdivision disagreement among the violins. 'Baião n' Blues' already isn't Assad's most compellingly structured piece, but a more honed performance might have made a better case. While Mahler sought to depict the world's natural beauty and bizarre juxtapositions in his music, he perhaps didn't anticipate contending with throbbing helicopters, the squeal of a coach's whistle, and hot rods sputtering down Lake Shore Drive on Friday. The Grant Park corps rose above the usual downtown backing track with a fresh, focused Mahler 1. Guerrero cued the unearthly, whistling first bars with an ambiguous gesture that invited the orchestra to melt in freely. Offstage trumpets were piped through the crown of the pavilion stage, sounding mysteriously heaven-sent. When the theme arrived in the cellos, Guerrero maintained their levity and grace throughout the movement — and, in fact, throughout much of the piece, bringing an aerodynamic lightness even to the symphony's final cadence. Because Grant Park 'does things a little differently,' per Guerrero, Friday's performance reinserted Mahler's discarded 'Blumine' movement. Through a complex change of hands, the only surviving manuscript copy of 'Blumine' ended up in in New Haven, Connecticut, where it was rediscovered as part of the Mahler renaissance of the 1960s. If 'Blumine' is heard at all, it's usually as a standalone piece, for good reason: It's arresting but nearly always out-of-place amid the lustiness of the rest of the symphony. Friday's performance gave the same impression — gauzy and subtle, but stopping short of the richness and emotional abandon that would make a better case for its inclusion. Elsewhere, other idiosyncratic touches intrigued and often convinced: more perky staccatos by oboist Alex Liedtke, orchestral accents like bitter twists of a knife in the funeral march, and a slower reading of the klezmer-band interludes. In all, it endorsed Guerrero's warhorse chops as enthusiastically as his new-music acumen. Rain or shine, Grant Park is looking like a fair place to be under his baton.
Business Upturn
16 hours ago
- Business Upturn
Novo Nordisk's subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
By GlobeNewswire Published on June 21, 2025, 04:34 IST Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was published in The Lancet and presented at the American Diabetes Association (ADA) Scientific Sessions. 1,2 and presented at the American Diabetes Association (ADA) Scientific Sessions. Oral amycretin phase 1 data on the safety, tolerability and weight loss potential in people with overweight or obesity was also published in The Lancet. 3 Findings from the clinical trials indicate amycretin appeared tolerable with a safety profile consistent with other GLP-1 and amylin receptor agonists.1,2,3 Bagsværd, Denmark, 20 June 2025 – Novo Nordisk announces subcutaneous amycretin data being presented at the American Diabetes Association (ADA) 85 th Scientific Sessions in Chicago, US.1 Full results of two clinical trials evaluating the safety, tolerability and weight loss potential of subcutaneous and oral amycretin in people with overweight or obesity were published today in The Lancet medical journal.1,3 Amycretin is the first treatment that combines GLP-1 and amylin receptor agonism biology in a single molecule. The published and presented results from the once-weekly subcutaneous amycretin phase 1b/2a clinical trial showed that participants who received the treatment demonstrated significantly greater weight loss across the full range of doses investigated compared to placebo. Data being presented at ADA were collected from two parts of the trial; dose escalation (amycretin 60 mg), and dose escalation and maintenance (amycretin 20 mg, 5 mg and 1.25 mg).1,2 No plateauing in weight reduction was observed at the end of treatment (ranging from 20 to 36 weeks) with all tested doses, suggesting that a longer treatment duration may potentially contribute to additional weight loss.1,2 Estimated mean change in body weight from baseline with once-weekly subcutaneous (SC) amycretin: 1,2 * Dose Treatment % Weight change % Weight change duration (SC amycretin) (placebo) 60 mg 36 weeks -24.3% -1.1%20 mg** 36 weeks -22.0% 1.9%5 mg** 28 weeks -16.2% 2.3% 1.25 mg** 20 weeks -9.7% 2.0% * If all people adhered to treatment i.e. if all people followed the planned dosing schedule for the full trial period without any treatment discontinuations. ** Administered during a 12-week maintenance period. Once-weekly subcutaneous amycretin treatment escalated up to 60 mg appeared tolerable with a safety profile consistent with other GLP-1 and amylin receptor agonists.1,2 The number of treatment-emergent adverse events (TEAEs) increased in a dose-dependent manner, were mostly gastrointestinal, and were comparable to the rate and profile of TEAEs reported in early-phase studies of GLP-1 receptor, GLP-1 receptor/gastric inhibitory polypeptide (GIP) receptor, and amylin receptor agonists.1,2 The majority of TEAEs were mild to moderate in severity and resolved by the end of the study period.1,2 Of the participants who discontinued the trial, the majority were due to non-TEAE reasons.1,2 'As pioneers in obesity innovation, we are exploring multiple biological pathways to develop potentially transformative medicines that support the individual needs and preferences of people with obesity on their weight loss journey towards overall improved health,' said Martin Holst Lange, executive vice president for Development at Novo Nordisk . 'Amycretin is the first investigational treatment that combines GLP-1 and amylin receptor agonism biology in one molecule, working on distinct pathways and offering complementary effects on appetite control. The findings published and presented today are encouraging. We are excited to advance the clinical development of subcutaneous and oral amycretin into phase 3 to assess its potential as a therapeutic option for weight management.' The published once-daily oral amycretin phase 1 clinical trial data showed that participants receiving amycretin achieved greater weight loss compared to placebo.3 After 12 weeks of treatment with amycretin up to 50 mg and up to 2 times 50 mg, participants achieved a mean change in body weight of -10.4% and -13.1% respectively, compared to -1.2% with placebo.3 There were no apparent signs of weight loss plateauing within the 12 weeks of treatment in either of these amycretin-treated groups.3 Once-daily oral amycretin appeared to have an acceptable safety profile and was tolerable in all tested doses, with TEAEs in line with what was expected from targeting GLP-1 and amylin receptors.3 All reported TEAEs occurred in a dose-proportional manner, were mild to moderate in severity, and mostly gastrointestinal. No new safety signals appeared during the study.3 Based on the findings from the oral and subcutaneous amycretin trials, Novo Nordisk recently announced it will advance amycretin into phase 3 trials to further investigate the treatment as a potential new therapeutic option for weight management.4 About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults with overweight or obesity and for adults with type 2 diabetes. Amycretin is developed for subcutaneous and oral administration. Oral amycretin Phase 1 trial – The trial evaluated the single-ascending dose and multiple ascending doses for oral amycretin, up to 2 times 50 mg, in 144 people with overweight or obesity, with a total treatment duration of up to 12 weeks. Subcutaneous amycretin Phase 1b/2a trial – The trial investigated the safety, tolerability, pharmacokinetics, and proof-of-concept of once-weekly subcutaneous amycretin in 125 people with overweight or obesity. The trial was a combined single ascending dose, multiple ascending dose and dose-response trial investigating three different maintenance doses with a total treatment duration of up to 36 weeks. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information _______________________ References The Lancet: Dahl K, Toubro, S, Dey S, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: Results of a randomised, controlled, phase 1b/2a study. Dahl, K, et al. (2025). Amycretin, a Novel, Unimolecular GLP-1 and Amylin Receptor Agonist: Results of a Phase 1b/2a Clinical Trial. Poster 2002-LB. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025. The Lancet: Gasiorek A, Heydorn A, Gabery S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, randomised, placebo-controlled study. Novo Nordisk Company Announcement. Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development. Available at: Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
16 hours ago
Diabetes drug may cut migraine days in half with little weight loss: Study
Drugs in the same family as Ozempic and Wegovy are known for treating diabetes and helping with weight loss, but a small, early-stage study suggested they might also ease migraines -- even when there's no weight loss. The benefit appears to come from lowering pressure in the brain, Dr. Simone Braca, a neurologist at the University of Naples Federico II and lead author of the study, explained to ABC News. 'This study is very interesting in that the GLP 1s are hypothesized to lower brain pressure, which can then lower your chance of getting a headache or a migraine,' Braca said. The small, 12-week study tracked 26 adults with obesity who had chronic or frequent migraines. Published in Headache -- the official journal of the American Headache Society -- and presented at this week's European Academy of Neurology meeting in Finland, it tested liraglutide, a type of GLP-1 drug commonly used for diabetes and weight loss. After taking a daily 1.8 mg dose of liraglutide for three months -- the amount typically used to treat diabetes -- their average number of headache days per month dropped from 20 to about nine. Participants also reported less disability from migraines, with scores on a standard headache impact scale cut by more than half. Although some participants lost a small amount of weight, Braca said the few lost pounds were not meaningful enough to explain the improvement in migraines. Instead, Braca pointed to pressure from cerebrospinal fluid -- the liquid that surrounds and cushions the brain and spine. He said he believes that even slight buildups of this fluid can press on nearby veins and nerves in the brain, potentially triggering migraines. 'An increased pressure of the spinal fluid in the brain may be one of the mechanisms underlying migraine,' Braca said. 'And if we target this mechanism, this preliminary evidence suggests that it may be helpful for migraine.' Nearly half of patients reported at least a 50% reduction in headache days, according to the Headache paper. About 40% experienced mild side effects like nausea or constipation. None stopped taking the medication. With such promising results, Braca and his research team, led by Dr. Roberto De Simone, are already planning larger trials. Future studies will measure brain pressure more directly and explore whether other GLP 1 drugs might also offer the same relief but with fewer side effects. 'There are still a substantial portion of migraine patients that face an unmet need and that live with its burden,' he said. 'New drugs that could target other pathways, I think that could be reassuring to those patients and give them hope.' The study adds to growing evidence that GLP-1 drugs may have benefits beyond diabetes and weight loss. Researchers are already studying these medications for a range of other conditions, including reducing the risk of heart disease and stroke, easing symptoms of addiction and treating Alzheimer's disease.
